Investigation of insulin-like growth factors/insulin-like growth factor binding proteins regulation in metabolic syndrome patients.

Tytuł:: Investigation of insulin-like growth factors/insulin-like growth factor binding proteins regulation in metabolic syndrome patients.
Autorzy:: Pouriamehr S; Department of Biology, Dezful Branch, Islamic Azad University, Dezful, Iran.
Barmaki H; Department of Laboratory Medicine, Faculty of Para Medical Sciences, Shahid Behest University of Medical Sciences, Tehran, Iran.
Rastegary M; Department of Biology, Basic Science Faculty, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Lotfi F; Department of Clinical Biochemistry, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. .
Nabi Afjadi M; Institute of Biochemistry and Biophysics, Tehran, Iran.
Źródło:: BMC research notes [BMC Res Notes] 2019 Oct 11; Vol. 12 (1), pp. 653. Date of Electronic Publication: 2019 Oct 11.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: London : Biomed Central, 2008.
MeSH Terms:: Insulin-Like Growth Factor Binding Proteins/*metabolism
Metabolic Syndrome/*metabolism
Somatomedins/*metabolism
Adult ; Biomarkers/blood ; Blood Glucose/metabolism ; Female ; Humans ; Insulin/blood ; Insulin-Like Growth Factor Binding Protein 3/blood ; Insulin-Like Growth Factor Binding Protein 3/metabolism ; Insulin-Like Growth Factor Binding Proteins/blood ; Insulin-Like Growth Factor I/metabolism ; Insulin-Like Growth Factor II/metabolism ; Iran ; Male ; Metabolic Syndrome/blood ; Metabolic Syndrome/diagnosis ; Middle Aged ; Risk Factors
References:: Metab Syndr Relat Disord. 2012 Feb;10(1):3-13. (PMID: 22103319)
J Clin Endocrinol Metab. 1998 May;83(5):1467-71. (PMID: 9589640)
Diabetes Metab Res Rev. 2013 Sep;29(6):452-62. (PMID: 23576494)
Clin Endocrinol (Oxf). 2014 Jun;80(6):773-81. (PMID: 24593700)
Diabetes Care. 2012 Apr;35(4):768-73. (PMID: 22374641)
Acta Diabetol. 2010 Mar;47(1):5-14. (PMID: 19771387)
Metabolism. 1994 Feb;43(2):199-203. (PMID: 8121302)
J Clin Endocrinol Metab. 1998 Feb;83(2):499-502. (PMID: 9467564)
J Transl Med. 2016 Jan 06;14:3. (PMID: 26733412)
Eur J Endocrinol. 2012 Sep;167(3):353-62. (PMID: 22715478)
Metabolism. 1990 Jun;39(6):584-7. (PMID: 2352477)
Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):371-6. (PMID: 16915540)
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1479-84. (PMID: 20378848)
J Clin Med. 2014 Dec 22;3(4):1561-74. (PMID: 26237614)
Eur J Endocrinol. 2014 Jul;171(1):9-19. (PMID: 24743393)
Peptides. 2014 Jun;56:94-110. (PMID: 24721335)
J Clin Invest. 1981 May;67(5):1361-9. (PMID: 7194884)
Contributed Indexing:: Keywords: Insulin-like growth factor; Insulin-like growth factor receptor; Metabolic syndrome X
Substance Nomenclature:: 0 (Biomarkers)
0 (Blood Glucose)
0 (IGFBP3 protein, human)
0 (Insulin)
0 (Insulin-Like Growth Factor Binding Protein 3)
0 (Insulin-Like Growth Factor Binding Proteins)
0 (Somatomedins)
67763-96-6 (Insulin-Like Growth Factor I)
67763-97-7 (Insulin-Like Growth Factor II)
Entry Date(s):: Date Created: 20191012 Date Completed: 20200225 Latest Revision: 20200225
Update Code:: 20240104
PubMed Central ID:: PMC6788073
DOI:: 10.1186/s13104-019-4492-9
PMID:: 31601230
: Czasopismo naukowe

Pełny tekst

Objective: The insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are thought to play a significant role in metabolic pathways and glucose metabolism. Unregulated levels of IGFs/IGFBPs have been associated with the development of glucose intolerance and metabolic syndrome X (MSx). We hypothesized that change of IGFs/IGFBPs levels could increase the risk of MSx; thus, this study aimed to evaluate the serostatus of IGFs/IGFBPs in individuals with MSx.
Results: After adjustment for metabolic parameters, MSx patients had a lower level of IGF-1, IGFBP-1, and IGFBP-2 compared with subjects in the control group. Further analysis revealed a positive correlation between serum levels of IGF-1 and IGF-2 (p < 0.05), as well as serum IGFBP-3 and IGF-2 (p < 0.05). Also, the statistical analysis showed a negative association of serum IGF-1 with plasma glucose and total cholesterol levels (p < 0.05). Besides, a negative relationship was found between serum concentrations of IGF-1/IGF-2 and the risk of developing MSx. These data indicated that some components of IGFs/IGFBPs are linked with the pathogenesis of MSx. In conclusion, these inverse associations showed a possible linkage between the IGF/IGFBP signaling pathway and the development of MSx. It seems the decreased concentrations of IGFs edmay be regarded as a potential biomarker for early diagnosis or even prognosis of MSx but need more systematic studies to confirmed it.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja